IceCure Medical (ICCM) Cash from Operations (2020 - 2026)

IceCure Medical (ICCM) has reported Cash from Operations for 7 consecutive years, with -$3.9 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Cash from Operations fell 37.87% year-over-year to -$3.9 million in Q2 2026; TTM through Jun 2026 was -$15.9 million, a 11.79% decrease from a year earlier, with the FY2025 full-year figure at -$14.6 million, down 16.01% from the prior year.
• Cash from Operations was -$3.9 million for Q2 2026 at IceCure Medical, up from -$4.3 million in the prior quarter.
• Over five years, Cash from Operations peaked at -$2.3 million in Q4 2023 and troughed at -$5.0 million in Q4 2025.
• A 5-year average of -$3.5 million and a median of -$3.3 million in 2022 frame the typical range for Cash from Operations.
• Across the five-year window, Cash from Operations plunged 120.31% in 2022 and jumped 44.19% in 2023, its largest moves.
• Over 5 years, Cash from Operations stood at -$4.1 million in 2022, then jumped by 44.19% to -$2.3 million in 2023, then plunged by 82.07% to -$4.2 million in 2024, then declined by 19.64% to -$5.0 million in 2025, then climbed by 22.75% to -$3.9 million in 2026.
• The last three Cash from Operations figures came in at -$3.9 million (Q2 2026), -$4.3 million (Q1 2026), and -$5.0 million (Q4 2025), per Business Quant data.